Literature DB >> 1522805

Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices.

M Petri1, D Spence, L R Bone, M C Hochberg.   

Abstract

Known risk factors for coronary artery disease are very common in the Hopkins Lupus Cohort, in spite of the fact that the average patients age is only 38.3 years. Three or more known risk factors were found in 53% of patients. Risk factors for CAD were common even in patients not on a regimen of prednisone therapy during their cohort follow-up. Hypercholesterolemia increased significantly with greater average prednisone dose. Despite the frequency of risk factors, patients' awareness of the risk of CAD was low, with only 16.9% of patients believing they were at high risk for developing CAD within 5 years. In general, awareness of individual risk factors was lower in black than in white patients with SLE. Preventive practices were most commonly addressed towards hypertension. Preventive practices directed against obesity, hypercholesterolemia, and smoking were underutilized. Whether these known risk factors are sufficient in and of themselves to explain the high frequency of CAD in the cohort (8%) or whether they are "enabling" factors acting upon endothelium damaged by immune-complex disease cannot be addressed by this study. However, both further investigation of these risk factors and attention to lifestyle and pharmacologic approaches to risk factor reduction are indicated by this study.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1522805     DOI: 10.1097/00005792-199209000-00004

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  49 in total

Review 1.  [The heart in rheumatic diseases].

Authors:  C Specker
Journal:  Internist (Berl)       Date:  2007-03       Impact factor: 0.743

Review 2.  The role of preventive cardiology in systemic lupus erythematosus.

Authors:  Jennifer Rae Elliott; Susan Manzi; Daniel Edmundowicz
Journal:  Curr Rheumatol Rep       Date:  2007-05       Impact factor: 4.592

Review 3.  Cardiovascular comorbidity in rheumatic diseases: a focus on heart failure.

Authors:  Kerry Wright; Cynthia S Crowson; Sherine E Gabriel
Journal:  Heart Fail Clin       Date:  2014-01-10       Impact factor: 3.179

4.  Modification of hypertension and hypercholesterolaemia in patients with systemic lupus erythematosus: a quality improvement study.

Authors:  M B Urowitz; D D Gladman; D Ibanez; Y Berliner
Journal:  Ann Rheum Dis       Date:  2006-01       Impact factor: 19.103

Review 5.  Pathogenesis and treatment of atherosclerosis in lupus.

Authors:  Maureen McMahon; Brian Skaggs
Journal:  Rheum Dis Clin North Am       Date:  2014-06-10       Impact factor: 2.670

Review 6.  Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.

Authors:  J A P Da Silva; J W G Jacobs; J R Kirwan; M Boers; K G Saag; L B S Inês; E J P de Koning; F Buttgereit; M Cutolo; H Capell; R Rau; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2005-08-17       Impact factor: 19.103

Review 7.  Atherosclerosis in autoimmune rheumatic diseases-mechanisms and clinical findings.

Authors:  Hasya Zinger; Yaniv Sherer; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

8.  Coronary artery aneurysm with systemic lupus erythematosus.

Authors:  Masaru Yoshikai; Masakatsu Hamada; Kyoumi Takarabe
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2004-08

9.  Factors associated with arterial vascular events in PROFILE: a Multiethnic Lupus Cohort.

Authors:  A M Bertoli; L M Vilá; G S Alarcón; G McGwin; J C Edberg; M Petri; R Ramsey-Goldman; J D Reveille; R P Kimberly
Journal:  Lupus       Date:  2009-10       Impact factor: 2.911

10.  Atherosclerosis risk factors in systemic lupus erythematosus.

Authors:  Surabhi Agarwal; Jennifer R Elliott; Susan Manzi
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.